6
Jan
2026
Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2025
Lilly Rolling in Obesity, Kymera Challenges Dupixent & Takeda Nails Tyk2
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Dec
2025
Small Molecules to Correct a Rare Kidney Disease: Emily Conley on The Long Run
Emily Conley is today’s guest on The Long Run. She is the CEO of Berkeley, Calif.-based Renasant Bio. The big idea at Renasant is to develop oral small molecule drugs to treat patients with autosomal dominant polycystic kidney disease, known as ADPKD. Patients with this disease develop cysts on their kidneys that sometimes cause the kidney to balloon in size... Read More
11
Dec
2025
5AM, OrbiMed Join $70M Bet on Prolynx Long-Lasting GLP-1 Weight Loss Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Dec
2025
PsiThera Gets $47.5M To Make Small Molecules Against TNF Superfamily
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Dec
2025
FDA Turmoil Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Merck Buys Cidara, Abbott Acquires Exact, & Function Flies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Building a Rare Disease Company: Neil Kumar on The Long Run
Neil Kumar is today’s guest on The Long Run. Neil is the founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma. BridgeBio got started a little more than 10 years ago with an idea of creating what it calls a “hub and spoke” business model for rare disease drug development. The hope was to find opportunities that were biologically compelling,... Read More
13
Nov
2025
Pfizer Grabs Metsera, Merck Delivers Oral PCSK9, & Kura Wins 1st FDA OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2025
Gate Bioscience Secures $65M To Turn Off Disease Proteins at the Source
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2025
Reinventing Drug Discovery with AI: Marc Tessier-Lavigne on The Long Run
Marc Tessier-Lavigne is today’s guest on The Long Run. Marc is the chairman and CEO of South San Francisco-based Xaira Therapeutics. Xaira is using computers to design protein drugs from scratch, building on work from co-founder David Baker’s lab at the University of Washington. Designing protein drugs on computers with ideal properties is a plenty big idea that won Baker... Read More
6
Nov
2025
Novo-Pfizer Bidding War, BillionToOne IPO, & FDA Turmoil
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Nov
2025
Manifold Bio Pockets $55M from Roche for Blood-Brain Barrier Shuttles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Oct
2025
Novartis Acquires Avidity for $12B, Novo Stiff-Arms Pfizer & Intellia Woes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2025
Innate Immune System Activators for Cancer: Art Krieg on The Long Run
Art Krieg is today’s guest on The Long Run. Art is the founder and CEO of a Cambridge, Mass.-based startup called Zola Therapeutics. Zola is developing an oligonucleotide drug candidate to activate a family of Toll-like receptors known as TLR7 TLR8 and TLR9. Activating these receptors is thought to spur the innate immune system to attack cancer cells. Art designed... Read More
23
Oct
2025
Takeda Bets on Innovent, NewLimit Lures Lilly, & Merck Makes in America
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2025
Novo Buys Akero, BMS Bets on Orbital In Vivo CAR-T, & a Biotech Industry Nobel
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2025
Creating a New Class of Medicines: Eric Fischer on The Long Run
Today’s guest on The Long Run is Eric Fischer. Eric is a professor at Dana Farber Cancer Institute in Boston. His structural biology and chemical biology expertise has led him down a path to become one of the world’s experts in an emerging category of medicine that includes targeted protein degraders and molecular glues. These novel chemical entities can be... Read More
6
Oct
2025
An Outstanding ‘Mini’ Traverse of Katahdin for Damon Runyon Cancer Research
The Timmerman Traverse for Damon Runyon Cancer Research Foundation had a spectacular experience on Mt. Katahdin in Maine on Saturday. Weather was glorious. Fall colors were vibrant. The team was fit and mentally ready for rocky, rugged terrain. They got a rich outdoor experience with a steep rock scramble on Cathedral Path, then crossing Katahdin’s famous Knife Edge ridge. This... Read More
6
Oct
2025
Arbor Takes Next-Gen Gene Editing into the Clinic, Secures Chiesi Partnership
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.